Navigation Links
CNS Response, Inc. Modifies rEEG(SM) Trial Protocol for 'Treatment-Resistant Depression' Study
Date:10/25/2007

rther, the fact that the treating physician was blind prevented the physician from considering the rEEGSM report alongside the standard clinical information of the patient when developing the treatment strategy. Of course, in clinical practice this integration of rEEG and clinical data is exactly what is done. So, this change will better mimic general clinical practice.

"As a result, we have concluded that a treatment design that attempts to blind the treating physician is operationally impractical. To adjust the design so that the measurement of outcomes is insulated from the treating physician, we will have an independent rater at all trial sites that will remain blind during the data collection and evaluation process. We will also use standard accepted patient self-rating scales as primary measures of outcome.

"Our interest in switching from TMAP, treatment algorithm to STAR*D is related to functionality and efficiency. The original study design involved comparing treatment results of patients guided using rEEGSM versus those directed by TMAP. However, one of TMAP's advantages in the field - providing multiple options to the treating physician - caused complications during the study.

"It was clear to our advisors that if we were to continue with the TMAP, a separate TMAP expert would be needed to guide the treating physicians. STAR*D, the nation's largest real-world study of depression, has recently completed an analysis suggesting treatment options with the highest probability of success for patients at various stages of treatment. By choosing the options shown to have the highest success, we can have a comparable arm with less variability and less need for expert interpretation. As such, we have concluded that the treatment design can be simplified by using the STAR*D results in the control arm of the study.

"Lastly, we encountered two obstacles with the trial subject qualifications that required attention. The first involved trial subje
'/>"/>

SOURCE CNS Response, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Man against HIV – new vaccine ready for human trials
2. FDA approves Phase 0 trial which tests experimental drugs on humans
3. Male contraceptive in trial
4. How do patients benefit of clinical trials
5. Glenmark’s new molecule to go through trial
6. Clinical trials need to be more frank
7. First head-to-head trials of once weekly Fosamax and Actonel therapies
8. Hormone Replacement Therapy increases the risk of endometrial cancer
9. Atrial fibrillation predicts for acute ischaemic stroke
10. Spray on contraceptive clears Phase I trial
11. The Indian Government has given the nod to conduct Human volunteer trials inorder to develop preventive AIDS vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 Effective today, the wellness ... Highmark Blue Cross Blue Shield Insurance. Owned by ... Nourish Nutrition and Health opened for business earlier ... Wexford. , The basis of the services ... informing clients on the simplicity of leading a ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 A ... business and technology startups is now available from ... marketing agency based in the Chicago region. The ... software and information technology (IT), services, ecommerce, healthcare, ... , Marketing disciplines critical to startup success include ...
(Date:7/30/2014)... Printing whole new organs for transplants sounds like something ... technology could one day make actual kidneys, livers, hearts ... In the ACS journal Langmuir , scientists are ... that takes them a step closer to realizing their ... , Yong Huang and colleagues note that this idea ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 The 3D ... seen and touched in our new 50,000 square foot ... (just behind Target). , Projectorscreenstore.com is one of the ... range of sophisticated technology and Audio/Visual products for education, ... with Makerbot, the leading manufacturer of 3D printers for ...
(Date:7/30/2014)... July 30, 2014 The Hearing Aid ... five years to 2014. Following a multiyear drop during ... demographic trends, the expansion of private healthcare coverage and, ... that Hearing Aid Clinics industry revenue will ... billion during the five years to 2014. , According ...
Breaking Medicine News(10 mins):Health News:Nourish Nutrition and Health Now Accepting Highmark Insurance 2Health News:Startup Marketing Practice Launched by Modern Marketing Partners 2Health News:Hearing Aid Clinics in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Hearing Aid Clinics in the US Industry Market Research Report Now Available from IBISWorld 3
... in the topoisomerase II alpha ( TOP2A ) gene ... compared with non-anthracycline-based regimens, according to a study in ... of the National Cancer Institute. The increased responsiveness ... tumors carry an amplification of the HER 2 ...
... Health & Science University Knight Cancer Institute will evaluate ... Seattle, Wash.) is as effective in delivering highly precise ... it has been in those with prostate cancer. , ... for prostate cancer, and it is our hope to ...
... Senior Living, Inc. (NYSE: SRZ ) today ... its Bank Credit Facility, which eliminates all financial covenants, ... 2009 maturity date."We are very pleased that our bank ... through its maturity date," said Mark Ordan, Sunrise,s chief ...
... NSAIDs can cause liver or stomach illness in ... (HealthDay News) -- Many over-the-counter painkillers and fever ... the potential danger of liver damage and stomach ... will have to include these warnings on all ...
... of the American Academy of Disaster Medicine,s (AADM), Gary ... from a disaster medicine perspective on the recent swine ... why improvements are needed to the U.S. public health ... or pathogen; how disaster medicine specialists are helping other ...
... Smithfield Foods, Inc. (NYSE: SFD ) ... no clinical signs or symptoms of the presence of ... its employees at its joint ventures in Mexico. As ... officials and are submitting samples from their swine herds ...
Cached Medicine News:Health News:Gene alterations associated with response to anthracycline therapy for breast cancer 2Health News:OHSU Knight Cancer Institute to study new radiation technology for head, neck cancer 2Health News:Sunrise Signs Twelfth Amendment to Bank Credit Facility through December 2, 2009 2Health News:Sunrise Signs Twelfth Amendment to Bank Credit Facility through December 2, 2009 3Health News:Sunrise Signs Twelfth Amendment to Bank Credit Facility through December 2, 2009 4Health News:FDA Adds New Label Warnings to Over-the-Counter Painkillers 2Health News:American Academy of Disaster Medicine's (AADM) President Comments on U.S. Public Health System, Discusses Swine Flu Infection and Prevention 2Health News:American Academy of Disaster Medicine's (AADM) President Comments on U.S. Public Health System, Discusses Swine Flu Infection and Prevention 3Health News:American Academy of Disaster Medicine's (AADM) President Comments on U.S. Public Health System, Discusses Swine Flu Infection and Prevention 4Health News:Smithfield Foods Says North American Influenza Not Present in Any of Its Worldwide Operations and Pork is Safe to Eat 2
(Date:7/30/2014)... PARIS , July 30, 2014 /PRNewswire/ ... Sanofi (EURONEXT: SAN and NYSE: SNY ) ... of alirocumab in people with hypercholesterolemia met their primary ... in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared ... monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... 2014  DigiPath, Inc. (OTCBB and OTCQB: DIGP), a ... cannabis testing and education markets, announced today that has ... not previously disclosed or, to its knowledge, any other ... "We have noticed unusual price and volume ... days," said Steve Barbee , CEO of DigiPath. ...
(Date:7/30/2014)... Coordinators, Inc. (PCI) is pleased to announce it has ... Limited (Penn Pharma). Penn Pharma is headquartered in Tredegar, ... Kingdom and operates regional offices in ... Tokyo , Japan. Penn Pharma offers both drug development ... manufacturing, as well as Clinical Packaging, Labeling, and global ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8DigiPath No New Corporate Developments 2PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5
... FDA approved Makena (hydroxyprogesterone caproate) in February 2011 ... births in women who have had at least one ... approved, a version of the active ingredient of Makena ... drug from a pharmacist who compounded the drug.  In ...
... N.J., Nov. 8, 2011 Covance Inc. (NYSE: ... Credit Suisse Healthcare Conference on Thursday, November 10, 2011 at ... the presentation at www.covance.com .  In order to register ... early. Covance, with headquarters in Princeton, New Jersey, ...
Cached Medicine Technology:FDA Statement on Makena 2Covance to Present at Credit Suisse 2011 Healthcare Conference 2
The Guidant Fineline II Sterox Atrial J is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
Steroid eluting pacemaker leads...
Medicine Products: